Intermittent Steroids Reduce Some Asthma Exacerbations

Share this content:
Intermittent Steroids Reduce Some Asthma Exacerbations
Intermittent Steroids Reduce Some Asthma Exacerbations

FRIDAY, May 27, 2016 (HealthDay News) -- There is strong evidence to support intermittent inhaled corticosteroids (ICS) for prevention of wheeze exacerbations in preschool children with intermittent asthma or viral-triggered wheezing, according to a review published online May 26 in Pediatrics.

Sunitha Kaiser, M.D., of the University of California, San Francisco, and colleagues analyzed 22 studies involving 4,550 children age 6 and younger. All had at least two episodes of asthma or wheezing in the previous year.

In 15 of the studies, children with persistent asthma or wheezing had a 30 percent reduction in the risk of exacerbation with daily medium-dose ICS use. Five other studies focused on more sporadic use of the inhalers by children whose wheezing was not persistent, and was typically only spurred by a cold. Those studies found a 35 percent reduction in exacerbations with high-dose intermittent ICS use compared to a placebo. Two more studies compared the effects of daily ICS and more sporadic ICS use in children with wheezing induced by common colds. Those studies found no difference in the number of exacerbations. There were no studies that compared daily-versus-intermittent use of ICS for children with chronic, daily asthma or wheeze.

"There is strong evidence to support daily ICS for preventing exacerbations in preschool children with recurrent wheeze, specifically in children with persistent asthma," the authors conclude. "For preschool children with intermittent asthma or viral-triggered wheezing, there is strong evidence to support intermittent ICS for preventing exacerbations."

Two authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »